Solid-tumor cancer patients ineligible for clinical trials receive more immunotherapy but may not benefit
Cancer patients who are ineligible for clinical trials receive immune checkpoint inhibitors (ICI) at greater rates than patients who are trial eligible despite no survival benefit, according to a new study by researchers ...
Nov 9, 2021
0
67